(Reuters) – Europe’s medicines regulator on Friday recommended to renew the conditional marketing authorization for Gilead Sciences’ remdesivir to treat COVID-19.
(Reporting by Vishwadha Chander in Bengaluru; Editing by Anil D’Silva)
EMA backs renewing conditional marketing approval for remdesivir in COVID-19 patients
May 21, 2021 | 7:53 AM
